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Site-1 protease function is essential 
for the generation of antibody 
secreting cells and reprogramming 
for secretory activity
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& Gina M. Doody  1
The unfolded protein response (UPR) and activation of XBP1 is necessary for high secretory efficiency 
and functional differentiation of antibody secreting cells (ASCs). The UPR additionally includes a branch 
in which membrane-bound transcription factors, exemplified by ATF6, undergo intramembrane-
proteolysis by the sequential action of site-1 (MBTPS1/S1P) and site-2 proteases (MBTPS2/S2P) and 
release of the cytoplasmic domain as an active transcription factor. Such regulation is shared with a 
family of CREB3-related transcription factors and sterol regulatory element-binding proteins (SREBPs). 
Of these, we identify that the CREB3 family member CREB3L2 is strongly induced and activated during 
the transition from B-cell to plasma cell state. Inhibition of site-1 protease leads to a profound reduction 
in plasmablast number linked to induction of autophagy. Plasmablasts generated in the presence of 
site-1 protease inhibitor segregated into CD38high and CD38low populations, the latter characterized 
by a marked reduction in the capacity to secrete IgG. Site-1 protease inhibition is accompanied by a 
distinctive change in gene expression associated with amino acid, steroid and fatty acid synthesis 
pathways. These results demonstrate that transcriptional control of metabolic programs necessary for 
secretory activity can be targeted via site-1 protease inhibition during ASC differentiation.
During terminal differentiation of B-cells to plasma cells (PCs), specific gene expression programs are instigated 
to allow adaptation to the secretion of large amounts of immunoglobulin. A critical role for the transcription 
factor XBP1 has been identified linking differentiation, ER stress and secretory apparatus expansion1,2. The initial 
data describing a role for XBP1 in PC generation was consistent with the secretion of immunoglobulin triggering 
an unfolded protein response (UPR)3. Later reports suggested that XBP1 could be expressed in cells that did not 
secrete immunoglobulin, challenging the idea that a UPR is required4,5. Furthermore, results from a B-cell con-
ditional knockout demonstrated that XBP1 was not required for the early stages of PC differentiation, but was 
required for efficient immunoglobulin secretion6. These data were additionally corroborated in another model of 
B-cell specific deletion of XBP1, linking XBP1 to the regulation of ER remodelling required for high rates of secre-
tion7. Unlike the proposed requirement for XBP1, available data suggest that both the PERK and ATF6 axes of 
the UPR may be dispensable for the formation of PCs8,9. Collectively, the available evidence suggests that B-cells 
utilize the UPR in an unconventional fashion10, and other components of the ER stress response may provide par-
tially redundant regulation of the secretory apparatus during PC differentiation. Amongst these the CREB family 
has not been explored in the context of B-cell differentiation.
CREB3L2 is one of 5 members of the CREB3 (CREB-cAMP response element binding protein) family11. This 
is a group of bZIP transcription factor proteins that are synthesized as latent ER resident transmembrane proteins 
and require protease cleavage in the Golgi to release the active transcription factor component12. The CREB3 
family members are implicated as evolutionarily conserved regulators of the secretory apparatus and potentially 
of the UPR. CREB3L2 and other CREB3 family members share their mechanism of activation with ATF6 and 
sterol regulatory element binding protein, SREBP, a major transcriptional regulator of sterol and lipid synthesis. 
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All of these factors are released from the ER, following appropriate stimulation, and migrate to the Golgi where 
they are cleaved by the sequential action of S1P and S2P11,13. This event releases the cytosolic transcription factor 
component that migrates to the nucleus and binds to DNA, regulating gene expression.
The sequential process of intramembrane proteolysis controlled by S1P and S2P provides a potential ave-
nue for therapeutic intervention targeting the group of transcription factors sharing this process of regulation. 
Evaluation of the pathway was originally performed in relation to control of the SREBP in the context of potential 
control of hepatic lipid synthesis14. This led to the development of a selective inhibitor and tool compound for 
selective dissection of the pathway in cell biology. Here, we describe the progressive accumulation of CREB3L2 
during PC differentiation and utilize the selective S1P inhibitor PF-429242 to establish that S1P-regulated events 
are essential for efficient ASC differentiation and regulation of genes involved in the metabolic pathways neces-
sary for adaptation to antibody secretion. This pathway reinforces the direct link between the secretory apparatus 
and the establishment of ASC state.
Results
CREB3L2 is induced and processed to the active form during PC differentiation. After appro-
priate stimulation B-cells undergo a step-wise reprogramming for dedicated antibody secretion. Recent develop-
ments of in vitro models of human PC differentiation provide the opportunity to dissect the regulatory networks 
that govern this transition (Fig. 1A)15–17. In a detailed characterization of gene expression spanning multiple 
stages of human PC differentiation, CREB3L2 was identified as one of the genes mostly strongly induced in PCs, 
distinct from other CREB3 family members15. This pattern of expression, with CREB3L2 highly expressed in PCs 
compared to B-cells, is also conserved in mice18. Similarly, the level of the MBTPS1 (S1P) enzyme responsible 
for the first phase of CREB3L2 processing also increases with differentiation, while the MBTPS2 (S2P) enzyme 
remains stable (Fig. 1B). Furthermore, in the gene expression profiling experiments CREB3L2 has a similar 
dynamic to other TFs critical in PC differentiation such as IRF4. This contrasts sharply for example with the 
expression of IRF8, a negative regulator of PC differentiation (Fig. 1B)19,20.
Based on the gene expression data, CREB3L2 is predicted to increase as B-cells transition to antibody secreting 
cells (ASCs), however generation of the active transcription factor depends on regulated intramembrane proteolysis. 
To determine whether the protein expression of CREB3L2 correlated with mRNA levels and differentiation stage, 
human B-cells were isolated from normal donors and differentiated in vitro. CREB3L2 expression was evaluated at 
defined intervals corresponding to activated B-cells/pre-plasmablasts (day 3), plasmablasts (day 6/7) and PCs (day 
11+) (Fig. 1C)15,21. The results demonstrated the presence of two forms of CREB3L2, with molecular weights con-
sistent with the full-length (80 kDa) and processed form (60 kDa). The molecular weight of the processed form was 
independently verified by transfection of an expression construct encoding the transcriptionally active N-terminus 
(data not shown). Both forms were present at each time point, however in activated B-cells (day 3) there is very little 
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Figure 1. Expression of CREB3L2 in differentiating primary human B-cells. (A) Schematic of in vitro B-cell 
differentiation with key stages and phenotypes. (B) Relative mRNA expression levels for IRF4, IRF8, CREB3L2, 
MBTPS1 and MBTPS2 during in vitro generation of PCs derived from microarray data. (C) Protein expression 
of CREB3L2 during in vitro differentiation of primary human B-cells. The day of culture is indicated at the top. 
Intact and dashed arrows show migration of full-length protein and cleaved C-terminus, respectively.
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processed CREB3L2. Subsequent to this at the plasmablast and PC stages, CREB3L2 full-length and cleaved forms 
were increasingly expressed. Thus, the protein expression pattern agreed with the observed levels of mRNA, and 
demonstrated that CREB3L2 is both expressed and processed during PC differentiation.
S1P inhibitor blocks CREB3L2 processing but does not alter plasmablast to PC maturation. The 
pattern of CREB3L2 expression observed during PC differentiation is consistent with processing via intramembrane 
proteolysis. CREB3L2 is a single-pass type 2 membrane-spanning protein and its proteloytic cleavage occurs in the 
Golgi via sequential activities of firstly S1P, in an exposed luminal site, and secondly S2P which catalyses an intramem-
brane cleavage (Fig. 2A)22. The reversible, competitive aminopyrrolidineamide inhibitor for S1P, PF-429242, provides a 
tool compound with which to dissect the involvement of this pathway of transcription factor regulation14.
Since the maximal expression of CREB3L2 was observed at the plasmablast to PC transition we initially tested 
the impact of PF-429242 treatment during the window of maturation from plasmablast to PC. Indeed, treatment 
of maturing plasmablasts at each of the time points assessed with a dose of PF-429242 previously demonstrated 
to inhibit the processing of SREBP14 strongly reduced the expression of cleaved CREB3L2. This processing event 
thus provides an indicator of S1P pathway activity in both plasmablasts and PCs, which can be effectively sub-
ject to pharmacological inhibition (Fig. 2B). Additional bands were also observed in the Western blots, lower 
than the predicted molecular weight of full-length CREB3L2, which are consistent with the previously described 
non-glycosylated versions of the protein22.
Surface phenotype is a key indicator of progression through the differentiation from plasmablast to PCs and can 
be tracked using the combination of CD19, CD20, CD38 and CD138 (Fig. 1A). To determine whether inhibition of 
S1P at the plasmablast stage impacted on the acquisition of the PC phenotype, ASCs were treated with PF-429242 
or vehicle and analyzed at sequential time points by flow cytometry. However, there were no discernable changes in 
expression of CD19, CD20, CD38 or CD138 after treatment with the S1P inhibitor (Fig. 2C). Thus although effective 
in blocking CREB3L2 processing, PF-429242 treatment did not impact on phenotypic changes during ASC differ-
entiation. Furthermore PF-429242 treatment also did not appreciably impact on cell number over a range of doses 
spanning 0.5 μM to 15 μM (Fig. 2D,E) or secretion of IgM and IgG as assessed from culture supernatant (Fig. 2F,G).
Therefore, despite having a profound effect on CREB3L2 processing, inhibition of S1P with PF-429242 failed 
to substantially perturb the maturation of plasmablasts to the PC state as assessed by cell counts, surface pheno-
type and immunoglobulin secretion. This suggests that CREB3L2 or other S1P-regulated transcription factors are 
not essential for the late stages of ASC differentiation in vitro.
S1P inhibitor prevents generation of ASC from activated B-cells. On the other hand, analysis of 
gene expression in diffuse large B-cell lymphoma has shown that CREB3L2 is characteristic of the activated B-cell 
(ABC) subset23, and CREB3L2 protein is detectable in primary activated B-cells/pre-plasmablasts in the vitro 
model. At the activated B-cell stage, the cells are undergoing rapid proliferation, with as many as 3 divisions 
within the space of 24 h24. From day 3 to day 6 the cells continue to divide prior to completing differentiation, 
which is accompanied by exit from cell cycle. Thus, CREB3L2 and the S1P pathway may function in B-cells 
initiating the process of PC differentiation and during the process of cell proliferation. To address this question, 
activated B-cells at day 3 of differentiation were treated with PF-429242 or vehicle and samples were collected 
every 12 h until day 6. In control vehicle treated cells CREB3L2 was evident primarily in unprocessed form at 12 h, 
by 24 h the processed form was evident and both unprocessed and processed forms accumulated peaking at 60 h 
(Fig. 3A). Thus in the absence of PF-429242, CREB3L2 is rapidly upregulated and processed as activated B-cells 
commence the transition to the plasmablast state. Over the time course, inhibition of CREB3L2 cleavage by 
PF-429242 was accompanied initially by a loss of processed and increased full-length protein, first detected 24 h 
and maximal 36 h post-treatment. This was followed by a loss of both forms such that by 48 h processed CREB3L2 
was not detected and by 72 h PF-429242 had abrogated expression of CREB3L2.
Accompanying the inhibition in first processed and then total CREB3L2, we observed a marked reduction 
in cell number after exposure to PF-429242. After initial exposure cell numbers expanded equivalently at 12 h, 
24 h and 36 h, but from 48 h onward rapidly diverged with progressive loss of cell number in PF-429242 treated 
conditions (Fig. 3B). The loss of cell viability showed a dose-dependance, with less than 10% of cells surviving at 
48 h when treated with 15 μM PF-429242 (Fig. 3C). Thus the impact on population cell number showed a delayed 
kinetics consistent with the pattern of impact on protein expression.
The effects on cell number were further corroborated in a number of additional donors as an end-point assay 
after 3 days of PF-429242 treatment (Fig. 4A). Autophagy provides an adaptive response to misfolded protein in 
parallel with the UPR and provides a supportive pathway during plasma cell differentiation. Consistent with dif-
ferentiation under stress and the reduction in cell number, PF-429242 treatment also promoted the accumulation 
of LC3II relative to LC3I (Fig. 4B). Thus PF-429242 treatment during the activated B-cell to plasmablast transition 
has profound effects on the efficiency of population expansion and is accompanied by markers of autophagy as an 
indicator of cellular stress. This contrasts markedly with the lack of effect observed with similar treatment during 
the subsequent plasmablast to PC transition.
Based on the available data, CREB3L2 is a strong candidate for mediating UPR-associated programs down-
stream of S1P. However, the generation of active transcription factors by regulated intramembrane proteolysis, 
and S1P in particular, extends to prototypical sensors of ER stress such as ATF6. To determine whether S1P inhi-
bition similarly affected the other conventional arms of the UPR, lysates were assessed by immunoblotting with 
antibodies that recognize the active form of ATF6 (Fig. 4C). Consistent with S1P-regulated processing, treatment 
of differentiating B-cells with PF-429242, led to a loss of detectable ATF6. Thus, although CREB3L2 provides an 
effective read-out of S1P-pathway inhibition, the profound impact on ASC differentiation mediated by PF-429242 
during the activated B-cell to plasmablast transition is likely to involve concerted effects on several transcriptional 
pathways that share a similar mode of regulation.
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S1P inhibition distorts the plasmablast phenotype and alters secretory potential. Given the 
profound impact of S1P inhibitor on the number of plasmablasts generated from activated B-cells, we next exam-
ined whether this translated into an effect on phenotypic maturation. During the activated B-cell to plasmablast 
window, despite the dramatic impact on cell number, the progressive acquisition of CD38 associated with plas-
mablast/PC differentiation was not abrogated. Consistent with the delayed effects on cell number no phenotypic 
difference could be identified up to 36 h. From 48 h onward, while acquisition of CD38 expression was observed 
Figure 2. S1P-specific inhibitor PF-429242 blocks CREB3L2 processing. (A) Diagram of CREB3L2 structure 
with proteolytic cleavage sites. Act domain, Activation Domain. bZIP, Basic Leucine Zipper Domain. TM, 
Transmembrane Domain. (B) In vitro generated human ASCs were treated with 10 μM PF-429242 or vehicle 
control (dH2O) on the day that appears first (d6, d8, d10) and protein lysates generated on the day that appears 
subsequently (d8, d10, d13) were analyzed by Western blotting. Intact and dashed arrows show migration 
of CREB3L2 full-length protein and cleaved C-terminus, respectively. (C) In vitro differentiated human 
B-cells were treated with 10 μM PF-429242 or vehicle control (dH2O) at day 6 and analyzed subsequently for 
phenotype on the indicated days. Live cells were evaluated for expression of B-cell markers CD19 and CD20 
and ASC markers CD38 and CD138. Percentages of cells are shown within the quadrant gates. The experiment 
was performed with 4 donors, a representative donor is shown. (D) Samples treated as in part (B) were assessed 
for cell number using CountBright beads. (E) In vitro activated human B-cells from 4 donors were treated with 
indicated amount PF-429242 or vehicle control (dH2O) at day 6 and assessed for cell number at 48 h. Results are 
displayed as the percentage viable cells relative to control. Supernatants from samples in part (B) were analyzed 
by ELISA for production of (F) IgM and (G) IgG. Significance was determined by t-test.
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in PF-429242 treated cells, a separation into two more distinct populations of CD38high and CD38low cells was 
evident. Indeed, where CD38 was acquired a higher MFI was evident amongst PF-429242 cells (Fig. 5A,B).
Since the defining feature of ASCs is the ability to secrete antibodies, an ELISpot assay was employed to meas-
ure Ig production from purified cells. In vitro activated B-cells were treated with PF-429242 or vehicle on day 3 
for 72 h. On day 6, cells were sorted based on CD38 expression levels (CD38high and CD38low) and equal numbers 
were seeded for IgM and IgG ELISpot (Fig. 5C). In control cultures an equal number of cells from both CD38high 
and CD38low sorts were capable of secreting IgM, whereas the number of IgG secreting cells was slightly lower 
in the CD38low population. For PF-429242 treated samples, the number of IgM-secreting cells in the CD38high 
group was comparable to that observed in the control. In contrast, the number of IgM-secreting cells derived 
from the CD38low population was reduced by 2-fold or greater. The most profound effect of PF-429242 was on 
the generation of IgG-secreting cells, such that the number of IgG-producing was lower in both populations but 
was most reduced amongst the CD38low population (Fig. 5C right panels). Thus, treatment of activated B-cells 
with PF-429242 led both to a substantial reduction in total cell number and the generation of CD38low cells with 
a reduced immunoglobulin secretion capacity.
S1P regulates adaptive metabolic programs required for secretory activity. The changes in the 
characteristics described above suggest that inhibition of S1P might impact on the gene expression programs gov-
erning PC differentiation or survival. To determine the potential role that S1P-regulated pathways might play in 
this process, RNA samples were prepared from cells that had been treated from day 3 for 72 h with PF-429242 or 
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Figure 3. Kinetic and dose analysis of S1P-specific inhibitor PF-429242 during the early phase of ASC 
generation. (A) In vitro activated human B-cells were treated with 10 μM PF-429242 or vehicle control (dH2O) 
at day 3 and assessed for CREB3L2 processing at 12 h intervals. Representative results are shown from a total of 
7 donors. (B) Samples from part (A) were assessed for cell number at the indicated time points. Displayed are 
the average cell number ± standard deviation derived from 7 donors. (C) In vitro activated human B-cells from 
4 donors were treated with indicated amount PF-429242 or vehicle control (dH2O) at day 3 and assessed for cell 
number at 48 h. Results are displayed as the percentage viable cells relative to control.
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vehicle and processed for evaluation of gene expression. 439 genes were significantly upregulated and 404 genes 
significantly downregulated (FDR corrected p-value < 0.05 and fold-change >1.4) following treatment (Fig. 6A) 
(Supplementary Table S1). Genes upregulated after PF-429242 treatment included genes such as EGR2, MYB, 
MIR155HG, SPIB, NFKBIE and chemokines CCL22 and CCR7 associated with the activated B-cell state (Fig. 6B). 
In contrast genes downregulated following S1P inhibition included genes such as SCD, ALDOC, LDLR, INSIG1, 
MSMO1 and PFKFB4 which together comprise the primary components of the sterol biosynthesis pathway, as 
well as other metabolic genes. Notably, the expression of other important regulators of plasma cell differentiation, 
including PRDM1 and XBP1 was not altered (Supplementary Table S1). To assess differentially expressed genes 
systematically we applied an integrated gene signature and ontology analysis (Fig. 6C). This confirmed the signif-
icant association of genes which were upregulated following PF-429242 treatment with signatures of the activated 
B-cell state and NF-κB signaling, chemokine and cytokine signaling, and lysosomal components. In contrast, 
the signatures most significantly associated with genes down-regulated after PF-429242 treatment were related 
to SREBP controlled pathways and lipid metabolism, suggesting that a substantial proportion of the change in 
gene expression might be attributable to loss of SREBP processing and activation. However inhibition of S1P also 
affected genes linked to serine and amino acid synthesis and sets of genes linked to both signatures of mTOR 
signaling and regulation by IRF4. Collectively, these results are consistent with the impact of S1P inhibition on 
multiple linked transcriptional pathways, with CREB3L2 providing an indicator of sensitivity to S1P inhibition.
Discussion
The UPR is required during the transition from activated B-cell to the ASC state and XBP1 is a key component 
of the conserved response to ER stress10. However, data suggests that early ASCs can still form in the absence of 
XBP12,6,7 therefore posing the problem of how ASCs cope with their metabolic requirements prior to the expres-
sion of XBP1. These data suggest that additional arms of the UPR may be acting prior to or in conjunction with 
XBP1. It is also entirely conceiveable that different components of the UPR are engaged during the different 
phases of plasma cell generation. ATF6, the structurally homologous CREB3 family (including CREB3L2) and 
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Figure 4. S1P inhibition induces autophagy and affects multiple UPR-related TFs. (A) In vitro day 3 B-cells 
were treated with 10 μM PF-429242 or vehicle control (dH2O) for 72 h and were assessed for cell number using 
CountBright beads. Shown are the average cell numbers from 7 donors ± standard deviations. Protein lysates 
generated from day 3 cells treated for 72 h with 10 μM PF-429242 were evaluated for (B) autophagy markers or 
(C) CREB3L2 and ATF6 by Western blotting. Shown are representative results from 2 donors, a total of 7 donors 
were evaluated.
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the sterol regulatory element binding proteins (SREBPs) can be regulated by intramembrane proteolysis during 
the UPR25,26. Additionally, direct regulation via alternative pathways has been identified. For example, TLR signals 
can trigger XBP1 mRNA processing in the absence of an established UPR27, while insulin signalling can directly 
regulate the generation of processed SREBPs in specialised cell types28. Therefore transcription factor regulation 
linked to the UPR may also be controlled independently of ER stress.
Gene expression data has shown that CREB3L2 increases as B-cells transition to ASCs, prompting the hypoth-
esis that CREB3L2 may be a critical participant in adaptation to secretory load15,18. The generation of cleaved 
CREB3L2 coincides with immunoglobulin production and would fit with a response to ER stress. This pattern is 
similar to CREB3L2 expression in differentiating chondrocytes29. In this lineage, differentiation is accompanied 
by an increase in the production of cartilage matrix proteins, resulting in ER stress. In this setting, CREB3L2 is 
required for enhanced ER to Golgi trafficking and is essential for the generation of mature chondrocytes.
Figure 5. S1P inhibition alters phenotypic maturation and prevents antibody secretion. (A) In vitro activated 
human B-cells were treated with 10 μM PF-429242 at day 3 and analyzed at 12 h intervals. Live cells were 
evaluated for surface phenotype. (B) The levels of CD38 expression in the lower left quadrant (CD38 low) 
or upper left quadrant (CD38 high) were determined for 7 donors at the 72 h time point. Data depict the 
mean ± standard deviation with significance determined by t-test (**P = 0.003, ***P = 0.001). (C) Day 3 
human differentiated B-cells were treated with 10 μM PF-429242 or dH2O for 72 h. After the incubation, the 
cells were sorted based on CD38 (high and low). An equal number of sorted cells (2,000 cells) were used to 
quantify ASCs using ELISpot for IgM and IgG.
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Accompanying the change in TF protein expression, application of PF-429242 had a profound effect on the 
biology of differentiating B-cells. Treatment of activated B-cells with this tool compound led to a dramatic reduc-
tion in cell number that was mirrored by an increase in autophagy. Interestingly, PF-429242 treatment did not 
preclude the development of phenotypic plasmablasts nor did the compound have substantial effects on plasma-
blasts during the subsequent progression to the PC state. Indeed, amongst the small number of cells retaining the 
capacity to differentiate after PF treatment, CD38 levels and CD138 percentages were increased. Given the loss of 
TF protein expression it is unlikely that such cells were displaying resistance to S1P-inhibition, but instead may 
have more effectively engaged in adaptive responses, such as autophagy, that allowed differentiation despite the 
impact of S1P inhibition on metabolic pathways.
After an initial activating stimulus coupled to growth, differentiating B-cells undergo multiple divisions linked 
to repeated stochastic cell fate choices between further division, ASC differentiation or death. During this pro-
cess both the acquisition of CD38, particularly in the memory compartment, and class switch recombination 
are coupled to division number30–32. The data obtained with PF-429242 suggest that S1P-regulated pathways 
may alter the output during this phase of expansion. Overall the results showed a greater effect of PF-429242 on 
IgG secreting cells compared to IgM secreting cells. The explanation for this differential sensitivity potentially 
Figure 6. Gene expression analysis identifies distinct gene signature enrichment in PF-429242 treated 
plasmablasts. (A) Day 3 B-cells from 6 donors were treated with 10 μM PF-429242 or vehicle control (dH2O) 
and analyzed on day 6 using Illumina bead arrays. (B) Selected genes showing greater than 1.4-fold change in 
expression are depicted. (C) Enrichment of gene signatures was determined using a hypergeometric test against 
a curated set of 28,000+ signatures and ontology term associations. Enriched signatures and ontologies were 
clustered according to genes contributing to enrichment with summary labels shown on the right.
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relates to origin from memory versus naïve B-cells, although a direct effect on class switching cannot be entirely 
excluded. Alternatively, specific differences in the nature of secretory pathway adaption linked to isotype may be 
involved. To our knowledge, differences separating the generation of IgG and IgM ASCs are not well characterised 
at present and this will be interesting to explore in future. The more pronounced loss of secretion in the CD38low 
population, which have been postulated to represent short-lived ASCs, might be consistent with the idea that the 
level of plasma cell TFs affect the proportion of ASCs formed during each cell division32.
The gene expression data are consistent with the observed phenotypic and functional effects. S1P inhibition 
both delays the loss the markers of the activated B-cell state, and leads to impaired upregulation of a set of genes 
linked to a coherent set of genes connected to metabolic regulation. The genes which fail to be appropriately 
upregulated are linked to multiple aspects of metabolism, such as amino acid synthesis, steroid synthesis, and 
lipid/cholesterol biosynthetic processes. These data are in keeping with the prediction that S1P-regulated path-
ways might be altering the ability of differentiating cells to upregulate the necessary metabolic pathways essential 
for organelle expansion linked to increased secretory capacity, and the original targeting of the PF-429242 com-
pound to the regulation of the SREBPs.
In summary, the data identify CREB3L2 as a transcription factor up-regulated during PC differentiation, are 
consistent with control through a pathway of intramembrane proteolysis which can be inhibited via targeting 
of S1P, and provide a sensitive indicator of effective S1P inhibition. S1P inhibition shows a striking dichotomoy 
in B-cell differentiation with clear sensitivity leading to profound effects on cell number and function during 
the activated B-cell to plasmablast transition, contrasting with resistance to inhibition as assessed by a range 
of parameters during the transition of plasmablasts to PCs. These results suggest that there are differences in 
the S1P-regulated processes at these closely linked phases of B-cell differentiation, with S1P regulated pathways 
potentially acting through the regulation of genes required for secretory pathway adaptation prior demands 
of immunoglobulin production. The results suggest that CREB3L2, most likely in conjunction with ATF6 and 
SREBPs, is involved in the early commitment to ASC fate.
Materials and Methods
Reagents. Reagents utilized in the in vitro culture system include human IL-2 (Roche); IFN-γ (Sigma); IL-6, 
IFN-α and IL-21 (PeproTech); goat anti-human F(ab’)2 fragments (anti-IgM and -IgG; Jackson Immunoresearch); 
HybridoMax hybridoma growth supplement (Gentaur); Lipid Mixture 1, chemically defined (200X) and MEM 
Amino Acids Solution (50X; Sigma); and PF-429242 (Tocris Bioscience).
The antibodies employed for protein detection include CREB3L2 (NBP1-88697, Novus Biologicals), ATF6 
(40256; Novus Biological), ACTIN (A1978; Sigma), LC3A/B (Cell Signaling). The reagents utilized in flow 
cytometry assays include PE-conjugated anti-CD19 (LT19; Miltenyi Biotech), V450-conjugated anti-CD20 (2H7; 
E-Biosciences), PE-Cy7-conjugated anti-CD38 (HB7; BD Biosciences); APC-conjugated anti-CD138 (B-B4; 
Miltenyi Biotech); CountBright beads (Invitrogen) and 7-AAD (BD Biosciences).
Cell culture. Whole blood obtained from healthy volunteer donors was collected in EDTA tubes after 
informed consent. Approval for this study was provided by U.K. National Research Ethics Service via the Leeds 
East Research Ethics Committee (approval reference: 07/Q1206/47). All the experimental protocols were con-
ducted following standard procedures in compliance with the guidelines and regulations for Research Ethics 
Committees in the UK.
Peripheral blood mononuclear cells were isolated by density centrifugation followed by purification of total 
B-cells by negative selection using a memory B-cell isolation kit (Miltneyi Biotec). Procedures for the in vitro 
differentiation of B-cells have been described in detail elsewhere15.
Protein evaluation. Cells were lysed by RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 
1% NP40, 0.5% sodium deoxycholate, 0.1% SDS with the addition of protease inhibitors), loaded on to 
SDS-polyacrylamide gels and transferred to nitrocellulose membrane (Thermo Scientific). Membranes were 
probed with the appropriate antibodies and detected by Supersignal West Pico Chemiluminescent substrate 
(Thermo Scientific).
Flow cytometry. Approximately 2 × 105 cells per sample were stained with the indicated antibodies. 
Non-specific staining was blocked using buffer containing 10% BSA, human IgG (Sigma) and normal mouse 
serum (Sigma). Then, the cells were stained using directly conjugated isotype or antigen-specific antibodies. 
Live cells were gated using FSC/SSC characteristics and exclusion of 7-AAD (BD Biosciences). The phenotype 
was evaluated on an LSRIII flow cytometer (BD Biosciences) using DIVA software (BD Biosciences). Absolute 
cell counts were determined by CountBright bead assay (Invitrogen). Day 6 in vitro generated plasmablasts were 
labelled with anti-CD38 and 7-AAD prior to sorting on a BD Biosciences Influx.
ELISA and ELISpot assays. Secreted immunoglobulins were detected using ELISAs performed as per the 
manufacturer’s instructions for the human IgM quatification kit (E80–100, Bethyl Laboratories, Inc) and human 
IgG kit (E80–104). Similarly, ELISpot kits for the detection of human IgM and IgG (Mabtech) were performed as 
described in the manufacturer’s protocol. Images were taken using an AID ELISpot Reader System (Autoimmun 
Diagnostika).
Gene expression. RNA was extracted using TRIZol and subjected to DNAseI treatment (DNA Free, 
Ambion). RNA samples were amplified using Illumina Totalprep RNA Amplification Kit. Resulting cRNA sam-
ples were evaluated using whole-genome expression direct hybridization assay (HumanHT-12 v4 Expression 
BeadChips; Illumina). Data was processed as described previously21.
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Data Availability
The complete set of array data has been submitted to the NCBI Gene Expression Omnibus (GEO; http://www.
ncbi.nlm.nih.gov/geo) under accession number GSE118172.
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